Industry News
Biotechnology Industry News
Pfizer revs up to leave GSK in the dust as maternal RSV vax granted FDA breakthrough tag
Pfizer revs up to leave GSK in the dust as maternal RSV vax granted FDA breakthrough tag aarmstrong Wed, 03/02/2022 - 09:15
FDA slaps hold on Finch’s C. diff med to get info on COVID-19 screening for donor-derived therapy
FDA slaps hold on Finch's C. diff med to get info on COVID-19 screening for donor-derived therapy klahucik Wed, 03/02/2022 - 09:00
Novartis backs Epsilogen’s bid to turn ‘Cinderella antibody’ into new class of cancer drug
Novartis backs Epsilogen's bid to turn 'Cinderella antibody' into new class of cancer drug ntaylor Wed, 03/02/2022 - 06:04
Facing omicron ‘curveball,’ Inovio seeks endpoint switch amid fear it will strike out against original goal
Facing omicron 'curveball,' Inovio seeks endpoint switch amid fear it will strike out against original goal ntaylor Wed, 03/02/2022 - 04:39
Sanofi picks a ‘safe’ bet for Adagene’s antibody tech in $2.5B biobucks tie up
Sanofi picks a 'safe' bet for Adagene's antibody tech in $2.5B biobucks tie up mbayer Tue, 03/01/2022 - 20:05
Flagship unveils Vesalius with $75M to bankroll ambitious target of treating 90% of human illnesses
Flagship unveils Vesalius with $75M to bankroll ambitious target of treating 90% of human illnesses klahucik Tue, 03/01/2022 - 14:27
Epizyme trims workforce, pipeline for FDA-approved cancer drug Tazverik in cost-saving move
Epizyme trims workforce, pipeline for FDA-approved cancer drug Tazverik in cost-saving move mbayer Tue, 03/01/2022 - 13:18
RedHill’s second-try COVID pill staves off hospitalization in phase 2
RedHill's second-try COVID pill staves off hospitalization in phase 2 klahucik Tue, 03/01/2022 - 11:42
RedHill’s 2nd try COVID pill staves off hospitalization in phase 2
RedHill's 2nd try COVID pill staves off hospitalization in phase 2 klahucik Tue, 03/01/2022 - 11:42
AbbVie bets $130M on UCB spinout, bagging early-phase Alzheimer’s and depression prospect
AbbVie bets $130M on UCB spinout, bagging early-phase Alzheimer's and depression prospect ntaylor Tue, 03/01/2022 - 08:47
Pfizer fails phase 3 C. diff vaccine test but still spies possible path forward
Pfizer fails phase 3 C. diff vaccine test but still spies possible path forward ntaylor Tue, 03/01/2022 - 08:05
UPDATE: Editas shares boosted as patent office rules in favor of Broad’s CRISPR patents, but the fight will continue
UPDATE: Editas shares boosted as patent office rules in favor of Broad's CRISPR patents, but the fight will continue aarmstrong Mon, 02/28/2022 - 19:49
Intellia now has the data for No. 1 unanswered gene editing question: Does it last?
Intellia now has the data for No. 1 unanswered gene editing question: Does it last? aarmstrong Mon, 02/28/2022 - 14:56
Gemini CEO out the door as 80% of staff laid off, strategic review gets underway
Gemini CEO out the door as 80% of staff laid off, strategic review gets underway klahucik Mon, 02/28/2022 - 11:28
FDA sticks a fork in Reata’s treatment for chronic kidney disease
FDA sticks a fork in Reata’s treatment for chronic kidney disease mbayer Mon, 02/28/2022 - 11:00
Amryt’s shares tumble as FDA stiff-arms skin treatment, a month after EU delay revealed
Amryt's shares tumble as FDA stiff-arms skin treatment, a month after EU delay revealed aarmstrong Mon, 02/28/2022 - 10:56
Huadong buys into Heidelberg, signs nearly $1B deal to gain access to four cancer assets
Huadong buys into Heidelberg, signs nearly $1B deal to gain access to four cancer assets klahucik Mon, 02/28/2022 - 10:35
Blueprint marks protein degrader path in $632M biobucks pact with a Vant
Blueprint marks protein degrader path in $632M biobucks pact with a Vant klahucik Mon, 02/28/2022 - 08:50
Deaths in Keytruda combo study spur Celyad to pause trial of off-the-shelf CAR-T cell therapy
Deaths in Keytruda combo study spur Celyad to pause trial of off-the-shelf CAR-T cell therapy ntaylor Mon, 02/28/2022 - 06:37
Advantage Pfizer: GSK stops phase 3 trials of maternal RSV vaccine after seeing safety signal
Advantage Pfizer: GSK stops phase 3 trials of maternal RSV vaccine after seeing safety signal ntaylor Mon, 02/28/2022 - 05:41